Select Language
COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cephalosporin market reached a value of US$ 18.04 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 21.69 Billion by 2027, exhibiting at a CAGR of 2.97% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Cephalosporins are beta-lactam antibiotics that function in the way similar to penicillin. These broad-spectrum drugs help in treating numerous bacterial infections such as pneumonia, kidney infections, bone infections, meningitis and various sexually transmitted diseases (STDs). There are currently five generations of cephalosporin drugs available in the market with a slight difference in their antibacterial spectrum. These medicines are also differentiated on the basis their administration, excretion, absorption and the duration of the effect of cephalosporin on the body. There are two ways to administer cephalosporin drugs, namely, oral and intravenous (IV). A course of oral cephalosporins is generally used for curing minor infections that are easy to treat such as strep throat. Whereas, IVs are utilized for more severe infections, like meningitis, as these medicines reach tissues quickly than those administered orally.
At present, the rapidly increasing water and air pollution are the primary reasons for the prevalence of infectious diseases across the globe. This has provided a boost to the demand for cephalosporin drugs worldwide. Other than this, various organizations around the world are taking initiatives to improve the development and delivery of antibiotic treatments. One such program is the Global Antibiotic Research and Development Partnership (GARDP), which is a not-for-profit R&D organization formed by the Drugs for Neglected Disease initiative (DNDi) and World Health Organization (WHO). It focusses on the promotion of public-private partnerships for increasing R&D of new antimicrobial diagnostics and agents. The formation of these partnerships is expected to play a significant role in the growth of the cephalosporin market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cephalosporin market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on generation, route of administration and application.
Breakup by Generation:
Breakup by Route of Administration:
Breakup by Application:
Breakup by Region:
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Limited, Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Abbott, Sun Pharmaceutical Industries Limited, etc.
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2021 |
| Historical Period | 2016-2021 |
| Forecast Period | 2022-2027 |
| Units | US$ Billion |
| Segment Coverage | Generation, Route of Administration, Application, Region |
| Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Companies Covered | Allergan Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Limited, Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Abbott and Sun Pharmaceutical Industries Limited |
| Customization Scope | 10% Free Customization |
| Report Price and Purchase Option | Single User License: US$ 2499 Five User License: US$ 3499 Corporate License: US$ 4499 |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global cephalosporin market was valued at US$ 18.04 Billion in 2021.
We expect the global cephalosporin market to exhibit a CAGR of 2.97% during 2022-2027.
The high prevalence of numerous bacterial infections, such as pneumonia, kidney infections, bone
infections, meningitis, etc., is primarily driving the global cephalosporin market.
The sudden outbreak of the COVID-19 pandemic has led to extensive R&D activities for the introduction
of combination drugs, including cephalosporin, as an immediate option for effective treatment of the
coronavirus infected patients.
Based on the generation, the global cephalosporin market has been segmented into first generation,
second generation, third generation, fourth generation, and fifth generation. Among these, third
generation cephalosporin holds the majority of the total market share.
Based on the route of administration, the global cephalosporin market can be divided into injection and
oral. Currently, injection represents the largest market share.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin
America, and Middle East and Africa, where Asia Pacific currently dominates the global market.
Some of the major players in the global cephalosporin market include Allergan Plc., Bristol-Myers Squibb
Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Limited, Merck & Co. Inc., Novartis
International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Abbott, Sun
Pharmaceutical Industries Limited, etc.
10% Free customization
Purchase Options
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at
sales@imarcgroup.com